Next Article in Journal
Evolution of a Cohort of COVID-19 Infection Suspects Followed-Up from Primary Health Care
Next Article in Special Issue
A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants
Previous Article in Journal
Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers
Previous Article in Special Issue
Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids
Review

CFTR Modulators: Does One Dose Fit All?

1
Department of Pulmonology, Haga Teaching Hospital, Els Borst-Eilersplein 275, 2545 AA The Hague, The Netherlands
2
Central Hospital Pharmacy, Charlotte Jacobslaan 70, 2545 AB The Hague, The Netherlands
3
Department of Pulmonology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Youssef Daali
J. Pers. Med. 2021, 11(6), 458; https://doi.org/10.3390/jpm11060458
Received: 17 April 2021 / Revised: 10 May 2021 / Accepted: 12 May 2021 / Published: 24 May 2021
(This article belongs to the Special Issue Cystic Fibrosis and Personalized Medicine)
For many people with cystic fibrosis (pwCF), CFTR modulators will be the cornerstone of their treatment. These modulators show robust treatment effects at group level in pwCF with specific mutations. The individual effect however, is variable. In this review we will explain reasons for reconsideration of dosing regimens of CFTR modulating therapy in order to improve treatment response and prevent side effects. Since the effect of a drug depends on pharmacodynamics and pharmacokinetics, pharmacodynamics and pharmacokinetic properties of CFTR modulators will be discussed. Pharmacokinetic-pharmacodynamic relationships will be used to gain insight in dosage response and exposure response relationships. To understand the cause of variation in drug exposure, pharmacokinetic properties that may change due to CF disease will be explained. We show that with current insight, there are conceivable situations that give reason for reconsideration of dosing regimens, however many questions need to be unravelled. View Full-Text
Keywords: cystic fibrosis; CFTR modulators; pharmacodynamics; pharmacokinetics; exposure response relationship cystic fibrosis; CFTR modulators; pharmacodynamics; pharmacokinetics; exposure response relationship
MDPI and ACS Style

van der Meer, R.; Wilms, E.B.; Heijerman, H.G.M. CFTR Modulators: Does One Dose Fit All? J. Pers. Med. 2021, 11, 458. https://doi.org/10.3390/jpm11060458

AMA Style

van der Meer R, Wilms EB, Heijerman HGM. CFTR Modulators: Does One Dose Fit All? Journal of Personalized Medicine. 2021; 11(6):458. https://doi.org/10.3390/jpm11060458

Chicago/Turabian Style

van der Meer, Renske, Erik B. Wilms, and Harry G.M. Heijerman 2021. "CFTR Modulators: Does One Dose Fit All?" Journal of Personalized Medicine 11, no. 6: 458. https://doi.org/10.3390/jpm11060458

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop